Biotech entity
Every one of those 1 sits in a single category, funding. Of the tracked stories, 1 of 1 also mention FiscalAI, the most common co-covered peer. Moleculin Biotech, Inc. appears in 1 tracked Biotech story from August 17, 2026. The tracked stories average 2 original sources each.
Last mentioned: Aug 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, funding. Of the tracked stories, 1 of 1 also mention FiscalAI, the most common co-covered peer. Moleculin Biotech, Inc. appears in 1 tracked Biotech story from August 17, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Moleculin Biotech, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Q2 earnings released; EPS beats consensus
Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
Weiss Ratings reiterates Sell
Restated a 'sell (e+)' rating on MBRX shares in a research note
Wall Street Zen downgrades MBRX
Cut its rating from 'sell' to 'strong sell' in a research note
Jane Street Group discloses new MBRX position
Acquired 22,550 shares valued at approximately $75,000 during Q4 2025, per SEC filing, representing about 1.11% of the company
Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Source: dailypolitical.com · themarketsdaily.com
Moleculin Biotech, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
